Abstract
MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressing or degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leading causes of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despite a great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over the last decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated in carcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in the development and progression of LC. In this review, we propose to summarize the current understanding of miRNAs in LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognostic biomarkers and tools for treatment.
Keywords: miRNA, lung cancer, biomarker, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, exosome.
Current Pharmaceutical Design
Title:Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies
Volume: 23 Issue: 39
Author(s): Xiaohong Du, Jitai Zhang, Juping Wang*, Xiaoming Lin*Feng Ding*
Affiliation:
- Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Collaborative and Creative Center of Molecular Pathology and Personalized Medicine, Department of Pathology, Shantou University Medical College, Shantou, Guangdong 515041,China
- Department of Thoracic Surgery, The first Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000,China
- Department of Physiology, School of Basic Medical Sciences, Wenzhou Medical University, Chashan Campus, Wenzhou, Zhejiang 325035,China
Keywords: miRNA, lung cancer, biomarker, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, exosome.
Abstract: MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressing or degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leading causes of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despite a great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over the last decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated in carcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in the development and progression of LC. In this review, we propose to summarize the current understanding of miRNAs in LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognostic biomarkers and tools for treatment.
Export Options
About this article
Cite this article as:
Du Xiaohong , Zhang Jitai , Wang Juping *, Lin Xiaoming *, Ding Feng *, Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170714150118
DOI https://dx.doi.org/10.2174/1381612823666170714150118 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets Tools For Decision-Making In Older Cancer Patients. Role Of The Comprehensive Geriatric Assessment
Anti-Cancer Agents in Medicinal Chemistry Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Pharmacokinetics and Systems Pharmacology of Anti-CD47 Macrophage Immune Checkpoint Inhibitor Hu5F9-G4
Current Pharmacogenomics and Personalized Medicine Chemistry, Isolation, and Pharmaceutical Applications of Inulin
Current Drug Therapy Molecular Aspects of Stromal-Parenchymal Interactions in Malignant Neoplasms
Current Molecular Medicine IR-780 Dye-based Targeting of Cancer-associated Fibroblasts Improves Cancer Immunotherapy by Increasing Intra-tumoral T Lymphocytes Infiltration
Current Cancer Drug Targets Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction
Anti-Cancer Agents in Medicinal Chemistry The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer
Reviews on Recent Clinical Trials Chemical Synthesis and Medicinal Applications of Glycoporphyrins
Current Medicinal Chemistry Opportunities to Exploit Non-Neutralizing HIV-Specific Antibody Activity
Current HIV Research Synthesis and <i>In Vitro</i> Cytotoxic Evaluation of Novel Murrayafoline A Derived β-Amino Alcohols
Letters in Organic Chemistry Non-aspirin Non-steroidal Anti-inflammatory Drugs for the Primary Chemoprevention of Non-gastrointestinal Cancer: Summary of Evidence
Current Pharmaceutical Design Drug Sensitivity Testing for Cancer Therapy, Technique Analysis and Trends
Current Reviews in Clinical and Experimental Pharmacology Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry The Association Between the Chronic Use of Non-Steroidal Anti- Inflammatory Drugs and Oxidative and Inflammatory Markers in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) Meet Our Editorial Board Member
Current Drug Targets Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets